Regeneron Wins EC Clearance for Libtayo Dosing Flexibility

Zacks
Ouvrir sur Zacks
Regeneron Wins EC Clearance for Libtayo Dosing Flexibility

Regeneron Pharmaceuticals REGN announced that the European Commission (EC) has approved a more flexible dosing schedule for its cancer drug Libtayo (cemiplimab) across all six approved skin, lung and cervical cancer indications in the European Union.

The approval allows patients who have completed the initial 12 weeks of treatment with Libtayo 350 mg every three weeks to switch to a higher 700 mg dose administered every six weeks, with each infusion lasting 30 minutes.

Additionally, patients who tolerate their first 30-minute infusion of the 350 mg dose can receive subsequent infusions over 15 to 30 minutes.

The revised dosing options could reduce the frequency of clinic visits and treatment time, improving convenience for patients and caregivers while offering greater flexibility to healthcare providers.

The approval is supported by safety and efficacy data from Libtayo’s clinical development program, along with pharmacokinetic and pharmacodynamic modeling and simulation data. It covers all six of Libtayo’s approved indications in the EU, spanning advanced cutaneous squamous cell carcinoma (CSCC), adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation, basal cell carcinoma, non-small cell lung cancer (NSCLC) and recurrent or metastatic cervical cancer.

The approval is a positive development for Regeneron, as greater dosing flexibility could improve the treatment experience, support patient convenience and potentially strengthen Libtayo's competitive positioning in the oncology market.

Libtayo is also an important component of the company's broader oncology strategy, serving as the backbone for several investigational combination therapies.

Meanwhile, a supplemental Biologics License Application seeking approval of the alternative dosing regimen in the United States is under FDA review, with a decision expected in March 2027.

An approval in the United States could provide an additional opportunity to enhance Libtayo's commercial appeal.

REGN’s Robust Performance

REGN has put up a strong year-to-date performance. Shares have rallied 24.1% compared with the industry’s gain of 6.5%.

Zacks Investment Research
Image Source: Zacks Investment Research

The rally followed strong quarterly results, as solid demand for Eylea HD, the higher-dose version of Eylea, and higher profit-sharing from Dupixent helped offset declining sales of standard-dose Eylea.

Eylea HD is gaining traction, supported by steady label expansions.

REGN’s top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi SNY records global net product sales of Dupixent.  

Ongoing label expansions for Dupixent continue to drive strong sales growth and contribute meaningfully to profitability.

Progress across its oncology portfolio should support greater diversification of revenues and reduce reliance on any single franchise. The recent pipeline momentum and favorable regulatory developments have improved the outlook.

Its deep pipeline, including the potential launch of cemdisiran for generalized myasthenia gravis, provides additional growth opportunities.

Meanwhile, CytomX Therapeutics CTMX announced the achievement of a preclinical milestone for one of the lead programs under its collaboration with REGN, triggering a $5 million milestone payment to the former.

REGN has collaborated with CytomX on discovery activities to identify and validate conditionally active bispecific antibodies. Per the terms, Regeneron will be responsible for funding all preclinical and clinical development, as well as commercialization activities. CytomX is eligible to receive target nomination payments and preclinical, clinical, regulatory and commercial milestone payments totaling up to approximately $4 billion under the expanded agreement.

REGN currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


 

Discover the Stocks Our Experts Want to Own This Quarter

Each quarter, four Zacks editors compile their favorite stocks into one report. As a sign of the times, three of this quarter's picks can potentially cash in on the massive AI boom. One grew its commercial revenue more than 140% last quarter.

The fourth stock is an online retailer posting its most significant growth since the pandemic. Its shares jumped more than 25% after its last earnings report, then pulled back, giving investors a chance to capitalize on what could be a longer-term bullish trend.

Get Your Free Ultimate Four Report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
 
Sanofi (SNY): Free Stock Analysis Report
 
CytomX Therapeutics, Inc. (CTMX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research